Aquestive Granted Preliminary Injunction
WARREN, N.J., July 16, 2018 /PRNewswire/ -- Aquestive Therapeutics("Aquestive") announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against
Keith J. Kendall, CEO of Aquestive, said: "This decision once again demonstrates the significant value our intellectual property has created for Aquestive, its products and our partners." He added, "We continue to believe that DRL's challenge to our patents is without merit."
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. For more information, please visit our website, aquestive.com.
Media inquiries:Christopher Hippolytechristopher.firstname.lastname@example.org
Investor inquiries:Stephanie Carringtonstephanie.email@example.com
View original content:http://www.prnewswire.com/news-releases/court-ruling-in-favor-of-aquestive-therapeutics-enjoining-dr-reddys-laboratories-from-launching-its-generic-suboxone-product-300681098.html
SOURCE Aquestive Therapeutics
Subscribe to our Free Newsletters!